GB Sciences Valuation
| GBLX Stock | USD 0.01 0 84.37% |
GB Sciences seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of GB Sciences from inspecting the entity fundamentals such as Return On Asset of -0.21, shares outstanding of 379.21 M, and Gross Profit of (881.46 K) as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that GB Sciences' price fluctuation is out of control at this time. Calculation of the real value of GB Sciences is based on 3 months time horizon. Increasing GB Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GB Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GBLX Pink Sheet. However, GB Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0059 | Real 0.004233 | Hype 0.006057 | Naive 0.00522 |
The intrinsic value of GB Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GB Sciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GB Sciences helps investors to forecast how GBLX pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GB Sciences more accurately as focusing exclusively on GB Sciences' fundamentals will not take into account other important factors: GB Sciences Total Value Analysis
GB Sciences is currently expected to have valuation of 10.19 M with market capitalization of 8.21 M, debt of 397.31 K, and cash on hands of 53.96 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the GB Sciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.19 M | 8.21 M | 397.31 K | 53.96 K |
GB Sciences Asset Utilization
One of the ways to look at asset utilization of GBLX is to check how much profit was generated for every dollar of assets it reports. GB Sciences owns a negative utilization of current and long term assets of -0.21 %, losing $0.002082 for each dollar of current and long term assets held by the entity. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of GB Sciences shows how wasteful it operates for each dollar spent on its current and long term assets.GB Sciences Ownership Allocation
GB Sciences secures a total of 379.21 Million outstanding shares. GB Sciences owns 13.08 % of its outstanding shares held by insiders and 0.0 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.GB Sciences Profitability Analysis
Net Loss for the year was (530.87 K) with loss before overhead, payroll, taxes, and interest of (881.46 K).About GB Sciences Valuation
Our relative valuation model uses a comparative analysis of GB Sciences. We calculate exposure to GB Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GB Sciences's related companies.GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada. Growblox Sciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
8 Steps to conduct GB Sciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GB Sciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GB Sciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain GB Sciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GB Sciences' revenue streams: Identify GB Sciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GB Sciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish GB Sciences' growth potential: Evaluate GB Sciences' management, business model, and growth potential.
- Determine GB Sciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GB Sciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
GB Sciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 325 M | |
| Retained Earnings | -104.6 M |
Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.